Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
NCT ID: NCT05142709
Last Updated: 2024-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
600 participants
OBSERVATIONAL
2021-10-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
NCT06190652
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT05740995
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
NCT05978193
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
NCT05615129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.
Anti-PD-1 Immune Checkpoint Inhibitors
used as 1st line treatment for metastatic ESCC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-PD-1 Immune Checkpoint Inhibitors
used as 1st line treatment for metastatic ESCC.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients who provided informed consent by appropriate methods. In dead case, optout will be applicable.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kuai Le Zhao, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lvhua Wang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Kuaile Zhao, M.D.
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The 2nd affiliated hospital of Bengbu medical University
Bengbu, Anhui, China
The 2nd people's hospital of Anhui province
Hefei, Anhui, China
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital
Fuzhou, Fujian, China
The 1st affiliated hospital of Xiamen University
Xiamen, Fujian, China
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center
Shenzhen, Guangdong, China
The 4th affiliated hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Anyang cancer hospital
Anyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Wuhan University Zhongnan hospital
Wuhan, Hubei, China
Zhongnan University Xiangya Hospital
Changsha, Hunan, China
Huai'an first hospital
Huai'an, Jiangsu, China
Jiangsu cancer Hosipital
Nanjing, Jiangsu, China
Nantong cancer hospital
Nantong, Jiangsu, China
Yancheng the 3rd hospital
Yancheng, Jiangsu, China
The Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
The 1st affiliated hospital of Nanchang University
Nanchang, Jiangxi, China
The 2nd affiliated hospital of Nanchang University
Nanchang, Jiangxi, China
The First Affiliated Hospital of Air Force Medical University
Xi'an, Shaanxi, China
Fudan University Shanghai cancer center
Shanghai, Shanghai Municipality, China
Sichuan cancer hospital
Chengdu, Sichuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The 2nd affiliated hospital of Wenzhou medical university
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESO-Shanghai18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.